Drugs / AVT001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03895996 | Jun 2019 → May 2022 | type 1 diabetes mellitus | Avotres Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVT001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03895996 ↗ |
| Modality | Cell therapy | “autologous dendritic cell therapy AVT001” NCT03895996 ↗ |
| Route | Intravenous | “three monthly intravenous infusions” PMID 38916421 ↗ Jun 2024 |